Depletion of SNHG1 enhanced the anti-cancer activities of sorafenib against SR-HCC cells that were refractory to sorafenib-induced proliferation inhibition and apoptosis in vitro and in animal experiments. This evidence concerns the gene SNHG1 and hepatocellular carcinoma.